Effects of Dexamethasone or Celecoxib on Biliary Toxicity after Hepatic Arterial Infusion of 5-Fluorodeoxyuridine in a Canine Model

Cancer Research

Volumn 64, Issue 1, 2004, Pages 311-315

  Ensminger, William D ^a,b   Knol, James ^a   DeRemer, Susan ^a   Wilkinson, Erby ^a   Walker, Suzette ^a   Williams, David ^a   Maybaum, Jonathan ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BROXURIDINE; CELECOXIB; DEXAMETHASONE; DNA; FLOXURIDINE;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILE DUCT OBSTRUCTION; BILIARY TRACT DISEASE; CHOLANGIOGRAPHY; CONTROLLED STUDY; DRUG EFFECT; EPITHELIUM; LABELING INDEX; LIVER CELL; NONHUMAN; PRIORITY JOURNAL; SCLEROSIS; TOXICITY;

EID: 1642494806     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-2588     Document Type: Article

References (21)

1. Ensminger, W. D. Intraarterial chemotherapy for the treatment of hepatic metastases. In: V. T., DeVita, S. Hellman, S. A. Rosenberg, (eds.), Cancer: Principles and Practice of Oncology, Update Series, Vol. 1, pp. 1-11. Philadelphia: Lippincott, 1987.
2. Ensminger, W., Niederhuber, J., Dakhil, S., Thrall, J., and Wheeler, R. Totally implanted drug delivery system for hepatic arterial chemotherapy. Cancer Treat. Rep., 65: 393-400, 1981.
3. Niederhuber, J. E., Ensminger, W., Gyves, J., Thrall, J., Walker, S., and Cozzi, E. Regional chemotherapy of colorectal cancer metastatic to the liver. Cancer (Phila.), 53: 1336-1343, 1984.
4. Meta-Analysis Group in Cancer. Reappraisal of HA infusion in the treatment of nonresectable liver metastases from colorectal cancer. Meta-Analysis Group in Cancer. J. Natl. Cancer Inst. (Bethesda), 88: 252-258, 1996.
5. Ensminger, W. D. Intraarterial therapy. In: M. C. Perry (ed.), The Chemotherapy Source Book, Ed. 2, pp. 253-269. Baltimore: Williams & Wilkins, 1996.
6. Kemeny, M. M., Battifora, H., Blayney, D. W., Cecchi, G., Goldberg, D. A., Leong, L. A., Margolin, K. A., and Terz, J. J. Sclerosing cholangitis after continuous hepatic artery infusion of FUDR. Ann. Surg., 202: 176-181, 1985.
7. Hohn, D., Melnick, J., Stagg, R., Altman, D., Friedman, M., Ignoffo, R., Ferrell, L., and Lewis. B. Biliary sclerosis in patients receiving HA infusions of floxuridine. J. Clin. Oncol., 3: 98-102, 1985.
8. Shea, W. J. Jr., Demas, B. E., Goldberg, H. I., Hohn, D. C., Ferrell, L. D., and Kerlan, R. K. Sclerosing cholangitis associated with HA FUDR chemotherapy: radiographic-histologic correlation. Am. J. Roentgenol., 146: 717-721, 1986.
9. Doria, M. I. Jr., Shepard, K. V., Levin, B., and Riddell, R. H. Liver pathology following HA infusion chemotherapy. Hepatic toxicity with FUDR. Cancer (Phila.), 58: 855-861, 1986.
10. Kemeny, N., Seiter, K., Conti, J. A., Cohen, A., Bertino, J. R., Sigurdson, E. R., Botet, J., Chapman, D., Mazumdar, M., and Budd, A. J. HA floxuridine and leucovorin for unresectable liver metastases from colorectal carcinoma. New dose schedules and survival update. Cancer (Phila.), 73: 1134-1142, 1994.
11. Kemeny, N., Cohen, A., Bertino, J. R., Sigurdson, E. R., Botet, J., and Oderman, P. Continuous intrahepatic infusion of floxuridine and leucovorin through an implantable pump for the treatment of hepatic metastases from colorectal carcinoma. Cancer (Phila.), 65: 2446-2450, 1990.
12. Kemeny, N., Seiter, K., Niedzwiecki, D., Chapman, D., Sigurdson, E., Cohen, A., Botet, J., Oderman, P., and Murray, P. A randomized trial of intrahepatic infusion of fluorodeoxyuridine with dexamethasone versus fluorodeoxyuridine alone in the treatment of metastatic colorectal cancer. Cancer (Phila.), 69: 327-334, 1992.
13. Kemeny, N., Conti, J. A., Cohen, A., Campana, P., Huang, Y., Shi, W. J., Botet, J., Pulliam, S., and Bertino, J. R. Phase II study of hepatic arterial floxuridine, leucovorin, and dexamethasone for unresectable liver metastases from colorectal carcinoma. J. Clin. Oncol., 12: 2288-2295, 1994.
14. Kemeny, N., Conti, J. A., Sigurdson, E., Cohen, A., Seiter, K., Lincer, R., Niedzwiecki, D., Botet, J., Chapman, D., Costa, P., and Budd, A. A pilot study of hepatic artery floxuridine combined with systemic 5-fluorouracil and leucovorin. A potential adjuvant program after resection of colorectal hepatic metastases. Cancer (Phila.), 71: 1964-1971, 1993.
15. Kemeny, M. M., Adak, S., Lipsitz, S., Gray, B., MacDonald, J., and Benson III, A. B. Results of the intergroup [Eastern Cooperative Oncology Group (ECOG) and Southwest Oncology Group (SWOG)] prospective randomized study of surgery alone versus continuous hepatic artery infusion of FUDR and continuous systemic infusion of 5FU after hepatic resection for colorectal liver metastases. Proc. Am. Soc. Clin. Oncol., 18: 264a, 1999.
16. Kemeny, N., Huang, Y., Cohen, A. M., Shi, W., Conti, J. A., Brennan, M. F., Bertino, J. R., Turnbull, A. D., Sullivan, D., Stockman, J., Blumgart, L. H., and Fong, Y. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N. Engl. J. Med., 341: 2039-2048, 1999.
17. Zeng, Z. S., Zhang, Z. F., and Sigurdson, E. R. Toxicity study of hepatic artery infusion chemotherapy with massive dose FUDR rats. Surg. Oncol., 4: 147-155, 1995.
18. Andrews, J. C., Knol, J., Wollner, I., Knutsen, C., Smith, P., Prieskorn, D., and Ensminger, W. Floxuridine-associated sclerosing cholangitis. A dog model. Investig. Radiol., 24: 47-51, 1989.
19. Andrews, J. C., Knutsen, C., Terio, P., Prieskorn, D., and Ensminger, W. D. Hepatobiliary toxicity of 5-fluoro-2′-deoxyuridine. Intra-arterial versus portal venous routes of infusion. Investig. Radiol., 26: 461-464, 1991.
20. Wollner, I. S., Knutsen, C. A., Ullrich, K. A., Niederhuber, J. E., Crudup, J. W., Juni, J. E., Warber, S. L., Gyves, J., Stetson, P. L., and Ensminger, W. D. A dog model using an implanted system for protracted hepatic arterial chemotherapy. J. Surg. Res., 41: 510-517, 1986.
21. Thun, M. J., Henley, S. J., and Patrono, C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J. Nat. Canc. Inst. (Bethesda), 94: 252-266, 2002.